Ethnic differences in genetic polymorphisms in UDP-glucuronosyltransferase 1A1 (UGT1A1) were investigated among AfricanAmericans, Caucasians, and Japanese using samples obtained from 150 individuals for each population. Genotyping of ؊3279T>G in the phenobarbital-responsive enhancer module, TA repeats in the TATA box, 211G>A (G71R) and 686C>A (P229Q) in exon 1, and three single nucleotide polymorphisms (SNPs) (1813C>T, 1941C>G, and 2042C>G) in the 3-untranslated region in exon 5 was performed. Eight haplotypes of block 1 (exon 1 and its 5-flanking region) harboring the first four variations were assigned to each individual. The dominant haplotype for African-Americans was *28b (؊3279G;TA 7 ; 211G;686C) (0.446), whereas that for the Japanese was *1a (؊3279T; TA 6 ;211G;686C) (0.610). Frequencies of the two haplotypes *1a and *28b were comparable in Caucasians. Haplotype *6a (؊3279T;TA 6 ; 211A;686C) was characteristic of the Japanese, whereas haplotypes *36b and *37b (؊3279T;TA 5 and TA 8 ;211G;686C) were found mostly in African-Americans. Although the three SNPs in block 2 (exons 2-5) were in complete linkage in the Japanese, they were not completely linked in African-Americans or Caucasians. These differences in haplotype distribution patterns among the three populations suggest the possibility of ethnic differences in toxicity profiles of drugs detoxicated by UGT1A1. A novel SNP, 686C>T (P229L), was found in an African-American. The intrinsic clearance of 7-ethyl-10-hydroxycamptothecin (SN-38) by P229L UGT1A1 expressed in COS-1 cells was about 3% of the wild type. The results of Western blotting and real-time reverse transcription-polymerase chain reaction suggest that the low glucuronidation activity of the variant was partly due to its low stability. The variation 686C>T may cause high toxicity during 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) therapy or hyperbilirubinemia in patients.
UDP-glucuronosyltransferases catalyze the glucuronidation of various lipophilic endogenous and exogenous substances including drugs and environmental toxicants to produce glucuronides. UDP-glucuronosyltransferase 1A1 (UGT1A1) is a member of the UGT1A family and is exclusively involved in the metabolism of bilirubin (Tukey and Strassburg, 2000) . It is also known to glucuronidate 7-ethyl-10-hydroxycamptothecin , the active metabolite of an anticancer drug, irinotecan (1-piperidino)-1-piperidino] carbonyloxycamptothecin), to form inactive 7-ethyl-10-hydroxycamptothecin glucuronide (SN-38G) (Iyer et al., 1998; Hanioka et al., 2001) . Since SN-38 is associated with severe diarrhea due to administration of CPT-11 (Araki et al., 1993) , detoxication of SN-38 by UGT1A1 could play a significant role in protecting against the severe side effects caused by CPT-11.
The wide interindividual variability in SN-38G formation in hepatic tissues is known and has been shown to correlate with UGT1A1 genetic polymorphisms (Iyer et al., 1999) . To date, a wide variety of allelic polymorphisms of human UGT1A1 have been reported, most of which lead to a partial or complete deficiency of enzyme activity and are associated with diseases, such as the Criegler-Najjar (CN) syndrome types I and II or Gilbert's syndrome, with hyperbilirubinemia and jaundice as main symptoms (http://som.flinders.edu.au/FUSA/ ClinPharm/UGT/1A1aalleles.html; Mackenzie et al., 1997; Tukey and Strassburg, 2000) . To understand these syndromes and their possible genetic causes, polymorphisms in the TATA box have been the most extensively studied. An inverse relationship between the number of TA repeats (five to eight) and transcriptional activity has been reported (Beutler et al., 1998) . It has been reported that serum bilirubin levels in individuals with seven TA repeats are higher than the levels in individuals without a seventh repeat (Bosma et al., 1995; Raijmakers et al., 2000) . Patients suffering from Gilbert's syndrome, CN syndrome, or prolonged neonatal jaundice also often carry seven or eight TA repeats (Iolascon et al., 1999; Burchell et al., 2000) . The UGT1A1 promoter polymorphisms are also considered a determinant of CPT-11 disposition and toxicity (Iyer et al., 1999; Ando et al., 2000; Iyer et al., 2002) . Other variations often associated with neonatal hyperbilirubinemia, CN syndromes, Gilbert's disease, or irinotecan toxicity are 211GϾA (G71R), 1456TϾG (Y486D), and 686CϾA (P229Q) (Ando et al., 2000; Kraemer and Klinker, 2002; Yamamoto et al., 2002) (In this report, the A of the translational start codon of the cDNA is designated 1.) Recently, the possibility of a synergistic effect of 3Ј-untranslated region variations with Ϫ3279TϾG on the bilirubin level and SN-38 pharmacokinetics was also proposed (Sai et al., 2004) . The single nucleotide polymorphism (SNP) Ϫ3279TϾG is located in the phenobarbital-responsive enhancer module, which is involved in activation of UGT1A1 transcription by the constitutive androstane receptor (Sugatani et al., 2002) .
A recent pharmacogenetic study has suggested that there are advantages in the use of haplotypes rather than individual SNPs to investigate the association between genotypes and phenotypes (Judson et al., 2000) . Racial variability in haplotype frequencies of UGT1A1 may contribute to an interpretation of the racial diversity of pharmacokinetics and toxicity of drugs metabolized by the enzyme. Recently, Sai et al. (2004) revealed the haplotype structure of UGT1A1 in Japanese cancer patients using Ϫ3279TϾG, TA repeats in the TATA box, 211GϾA, 686CϾA, and three SNPs (1813CϾT, 1941CϾG, and 2042CϾG) in the 3Ј-untranslated region in exon 5 as markers. Therefore, we studied in this report the differences in the haplotype frequencies of UGT1A1 among African-American, Caucasian, and Japanese populations using genomic DNA obtained from 150 individuals in each population, assessing the genotypes of these markers with dideoxy sequencing and pyrosequencing methods previously reported by Saeki et al. (2003) . The function of a novel SNP 686CϾT (P229L) that was found in an African-American individual during this study was also investigated by utilizing a heterologous expression system with COS-1 cells.
Materials and Methods
Materials. and SN-38G (lot 970507R) were kindly supplied by Yakult Honsha Co. Ltd. (Tokyo, Japan). COS-1 cells were obtained from the Health Science Research Resources Bank (Osaka, Japan). Other chemicals used were all reagent grade.
Peripheral Blood Samples. One hundred fifty peripheral blood samples were obtained from healthy Japanese volunteers, 100 of which were kindly provided by Professor Ichiro Ieiri from the Tottori University Hospital with permission of the ethics committees of the Tottori University Faculty of Medicine. Written informed consent was obtained from all participants. Peripheral blood samples of healthy Caucasian and African-American volunteers (150 each) were purchased from the Tennessee Blood Service Corporation (Memphis, TN). The ethics committee of the National Institute of Health Sciences approved this study.
UGT1A1 Genotyping by Pyrosequencing and Dideoxy Sequencing. Genotyping of UGT1A1 using Pyrosequence methods was performed as previously reported (Saeki et al., 2003) . Briefly, genomic DNA (10 -15 ng) was amplified by Ex-Taq (1 U; Takara Shuzo, Ootsu, Japan) with a specific primer pair in which one of the primers was biotinylated. The primers for amplification and sequencing used for detection of polymorphisms Ϫ3279TϾG, the TA repeat, 211GϾA (G71R), and 686CϾA/T (P229Q/L) have been shown previously (Saeki et al., 2003) . Genotyping of 1941CϾG for the Japanese samples was performed using an amplification primer pair (biotin-ATTTGAATATG-TATCGTGCCC and CATTCATTCATTTCACCTACACT) and a sequencing primer (CAGTAGGGGCAGC). Generation of the single-stranded fragment and annealing of the sequencing primers have been described previously (Saeki et al., 2003) . Genotypes were determined using the PSQ 96MA (Biostage AB, Uppsala, Sweden) and the PSQ 96 SNP reagent set (Biostage AB). Genotyping of 1813CϾT, 1941CϾG, and 2042CϾG for African-American and Caucasian samples as well as the detection of a genotype 686CϾT in the African-American individual were done by dideoxy sequencing as reported previously (Saeki et al., 2002; Sai et al., 2004) .
Haplotype Analysis. Genotyping was successfully determined for 150
Japanese, 147 Caucasians, and 148 African-Americans. Diplotypes (combinations of haplotypes) in both blocks 1 and 2 were inferred separately for each population by PHASE version 2.0 (Stephens et al., 2001; Stephens et al., 2003) . Expression and Enzyme Assay of Wild-Type and Variant UGT1A1s. Expression of wild-type and variant UGT1A1s in COS-1 cells was carried out as described previously (Jinno et al., 2003b ) with a minor modification; attB-flanked UGT1A1 cDNA was amplified by the two-step attB adaptor polymerase chain reaction (PCR) (Jinno et al., 2003a ) using pcDNA3.1-UGT1A1/WT (Jinno et al., 2003b) as a template and gene-specific primers, 5Ј-AAAAAGCAGGCTGCAAAGGCGCCATGGCTGT-3Ј and 5Ј-AGAAA-GCTGGGTCTCAATGGGTCTTGGATTTGTGGG-3Ј. The resulting PCR fragment was cloned into the pDONR201 vector (Invitrogen, Carlsbad, CA). The 686CϾT mutation was introduced into the wild-type UGT1A1 cDNA clone in pDONR201, using a QuickChange multisite-directed mutagenesis kit (Stratagene, La Jolla, CA) with the 5Ј-phosphorylated oligonucleotide primer 5Ј-phospho-GCGACGTGGTTTATTCCCTGTATGCAACCCTTGCCTC-3Ј (the nucleotide base changed is underlined). Subcloning of each UGT1A1 fragment from pDONR201 into pcDNA-DEST40, a mammalian expression vector, was performed by the Gateway LR reaction.
Expression levels of UGT1A1 mRNA and protein were determined as described previously (Jinno et al., 2003b) . SN-38 glucuronidation activity of the wild-type and P229L variant UGT1A1 was assayed according to the method of Hanioka et al. (2001) .
Data Analysis. The 2 test in the SAS Preclinical Package (SAS Institute Japan Ltd., Tokyo, Japan) was applied to s ϫ r contingency tables for comparison of genotype frequencies and analysis of haplotype distribution patterns among the three ethnic groups. In vitro Michaelis-Menten kinetic parameters were estimated by nonlinear regression analysis using Prism version 3.0 (GraphPad Software Inc., San Diego, CA). The average values of the kinetic parameters were calculated using results from three independent preparations. The t test supplied in Prism version 3.0 was applied to the comparison of the average values of protein expression and mRNA levels between wildtype and variant UGT1A1 at a significance level of 0.05.
Results

Differences in Allele Frequencies among Three Ethnic Groups.
Allele frequencies of polymorphisms in UGT1A1 tested in this study are summarized in Table 1 . The estimated allele frequency of Ϫ3279TϾG (UGT1A1*60; for UGT1A1 allele nomenclature refer to Mackenzie et al., 1997 and http://som.flinders.edu.au/FUSA/ ClinPharm/UGT/1A1aalleles.htm) was 0.847, 0.550, and 0.257 in African-Americans, Caucasians, and Japanese, respectively, and they were significantly different ( p Ͻ 0.0001 by the 2 test). Regarding the variation in the TATA box, the allele TA 6 was most common in the Japanese population, whereas frequencies of TA 6 and TA 7 (UGT1A1*28) were equally frequent in African-Americans. The allele frequencies of TA 5 (UGT1A1*36) or TA 8 (UGT1A1*37) in AfricanAmericans were about 5% , but no carriers with TA 5 or TA 8 were found in the Japanese. The allele distribution patterns for the wildtype and three variants in the TATA box of the three ethnic groups were significantly different ( p Ͻ 0.0001 by the 2 test). The variant 211GϾA (G71R) (UGT1A1*6) was frequently found in the Japanese population, but not in the Caucasians population (only two heterozygous subject), and none were found in African-Americans. The variant 686CϾA (P229Q) (UGT1A1*27) was very rare in all the ethnic groups, and only one heterozygous carrier was found in the Japanese group. A novel variation in the same position as the variant 686CϾA, but with a different nucleotide change (686CϾT), was found in an African-American. This novel variant led to an amino acid change from proline to leucine (P229L). Pyrograms for 686C/C, 686C/A, and 686 C/T are compared in Fig. 1A and the nucleotide change of the novel variant was confirmed by the dideoxy sequencing method (Fig.  1B) . This is the first report detailing allele frequencies of three SNPs in the 3Ј-untranslated region in exon 5, 1813CϾT, 1941CϾG and
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TA box 2042CϾG in African-Americans and Caucasians. The frequencies of 1813CϾT and 2042CϾG in the Japanese were not determined in this study, because these alleles were reported to be in complete association with 1941CϾG in a Japanese population without exception (Sai et al., 2004; unpublished data) . Therefore, allele frequencies of 1813CϾT and 2042CϾG in the Japanese were assumed to be equal to that of 1941CϾG. On the other hand, we found that 1813CϾT and 2042CϾG were not always in association with 1941CϾG in AfricanAmericans and Caucasians, as shown in Table 1 . The allele frequencies of the three SNPs were highest in African-Americans and lowest in the Japanese. Significant differences in the allele frequencies were detected ( p Ͻ 0.0001, p ϭ 0.0074, and p Ͻ 0.0001 for 1813CϾT, 1941CϾG, and 2042CϾG, respectively, by the 2 test). Differences in Haplotype Frequencies. Sai et al. (2004) previously reported that UGT1A1 could be divided into two blocks, with the transcription-regulating and promoter regions and exon 1 in block 1, and exons 2 to 5 in block 2, according to linkage disequilibrium analysis. Therefore, haplotype/diplotype analysis was performed using four marker variations in block 1 (Ϫ3279TϾG, 211GϾA, and 686CϾA, and the TATA box), and three marker variations in block 2 (1813CϾT, 1941CϾG, and 2042CϾG). The diplotype configurations (combinations of haplotypes) were estimated for each subject by PHASE software (Stephens et al., 2001; Stephens et al., 2003) .
Concerning block 1, the diplotype configurations were inferred with greater than 0.99 certainties for 145 Japanese, 144 Caucasians, and 147 African-Americans. The haplotypes identified are summarized in Table 2 along with their frequencies for each population, where the 14 subjects with ambiguous diplotypes were excluded. We followed the haplotype nomenclature previously reported (Sai et al., 2004) . One Japanese subject carrying heterozygous 686CϾA also carried homozygous TA 7 . Thus, the association of variation 686CϾA with TA 7 was also confirmed in this study, as previously reported by Huang et al. (2000) and Sai et al. (2004) . A new haplotype, designated *6d, having variations in both positions Ϫ3279 and 211, was identified that was not found in the previous study (Sai et al., 2004 ). We could not determine whether the novel variation 686T and the *28 allele were on the same chromosome, because the subject with 686T carried heterozygous TA repeats, TA 6 /TA 7 .
In block 1, haplotype *1a was predominant in the Japanese population (0.61 in frequency). In contrast, its frequencies in Caucasians and African-Americans were 0.45 and 0.15, respectively. Major haplotypes in African-Americans were *28b and *60a. Haplotype frequencies of *1a and *28b in Caucasians were comparable. Thus, the haplotype distribution patterns in block 1 for the individual populations were significantly different ( p Ͻ 0.0001 by the 2 test). In block 2, the diplotype configurations using the three SNPs were inferred with certainties greater than 0.98 for all Caucasians and African-Americans (150 each). The haplotypes and their frequencies are summarized in Table 3 . Four novel haplotypes, *IC, *ID, *IE, and *IF, were identified in the Caucasian and African-American populations, although *IE was not found in the latter. These haplotypes were not found in the Japanese, as shown in a previous study (Sai et al., 2004) . Although the three SNPS were reported to be completely associated with each other in the Japanese (Sai et al., 2004) , they were not always linked with each other in the rest of the populations. However, it is noteworthy that 1941G allele was always associated with 1813T and 2042G alleles except for the haplotype *IE, found only in two Caucasians. Haplotype *IA was predominant for all ethnic groups. The second major haplotype was *IB in both the Japanese and Caucasians. However, the frequencies of *IB and *IC were similar in African-Americans (0.183 and 0.163, respectively). The haplotype *IC was also found in Caucasians (0.06). Thus, the haplotype distribution patterns in block 2 for the three populations were also significantly different ( p Ͻ 0.0001 by the 2 test). 
Expression and SN-38 Glucuronidation of a Novel
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at ASPET Journals on August 14, 2017 dmd.aspetjournals.org sion level of the novel variant UGT1A1/P229L in the membrane fraction of COS-1 cells was determined by Western blotting using a polyclonal anti-human UGT1A antibody (Fig. 2) . Because two bands, one at the same position as the wild-type and the other at a higher molecular weight, were detected for P229L, the total chemiluminescence of the two bands was used to calculate the protein expression level for P229L. The protein expression level of P229L was approximately 60% of the wild type, and this difference was statistically significant by the t test ( p ϭ 0.044). The UGT1A1 mRNA expression level was then measured by real-time reverse transcription-PCR (RT-PCR) using SYBR Green. As shown in Fig. 3 , however, no significant difference in the mRNA level was detected among the COS-1 cells transfected with the expression plasmids carrying wild-type and P229L UGT1A1 cDNAs.
The glucuronidation activity of SN-38 by P229L expressed in COS-1 cells was compared with that of the wild-type under 11 substrate concentrations ranging from 2.5 to 150 M. The representative curves of the Michaelis-Menten kinetics are shown in Fig. 4 , and the estimated apparent kinetic parameters (K m , V max , and V max /K m ) are summarized in Table 4 . V max values normalized 
Haplotypes in block 2 (exons 2-5) of UGT1A1 for three ethnic groups
Haplotype distribution patterns in block 2 were statistically different among the three ethnic groups ( p Ͻ 0.0001 by the 2 test).
a Haplotypes in Japanese were determined according to the genotype of 1941C Ͼ G, because it was previously reported that all three markers were completely associated in a Japanese population.
TABLE 2
Haplotypes in block 1 (the enhancer/promoter regions and exon 1) of UGT1A1 for three ethnic groups
Haplotype distribution patterns in block 1 were statistically different among the three ethnic groups ( p Ͻ 0.0001 by the 2 test). Fourteen subjects with ambiguous diplotypes were excluded from the analysis.
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at ASPET Journals on August 14, 2017 dmd.aspetjournals.org to the expression levels are also shown. Wild-type UGT1A1 catalyzed SN-38 glucuronidation with an average apparent K m value of 8.67 M, whereas P229L catalyzed SN-38 glucuronidation with a K m value of 37.6 M. The average V max values were 71.2 and 5.27 pmol/min/mg membrane protein for the wild-type and P229L, respectively. The average intrinsic clearances of SN-38 by glucuronidation (V max /K m ) normalized to expressed UGT1A1 protein levels were 8.26 and 0.24 l/min/mg protein for the wild-type and P229L, respectively.
Discussion
There have been previous reports of the allele frequencies of variants in the TATA box in various ethnic groups (Beutler et al., 1998; Fertrin et al., 2002; Innocenti et al., 2002; Sugatani et al., 2002; Ki et al., 2003; Premawardhena et al., 2003; Sai et al., 2004) . According to these studies, allele frequencies of the wild-type TA 6 were highest in Polynesian people (0.97-0.99), followed by Asians, including Japanese, Koreans, and Taiwanese (0.81-0.92), and Caucasians (0.61-0.73). Allele frequencies were lowest in Africans (0.44 -0.52). The allele frequencies of TA 5 and TA 8 in Africans were reported as approximately 0.05, but were very rare in Caucasians and were not detected in Asians. The allele frequencies of the four genotypes in the TATA box in African-American, Caucasian, and Japanese populations observed in this study were in the ranges previously reported. Allele frequencies of other UGT1A1 variations have not been as extensively studied as those in the TATA box. The allele frequencies for the variant Ϫ3279TϾG were 0.17 to 0.27 in Japanese and Koreans (Sugatani et al., 2002; Ki et al., 2003; Sai et al., 2004) , 0.47 in Caucasians (Innocenti et al., 2002) , and 0.85 in African-Americans (Innocenti et al., 2002) . Thus, our data (0.257 for Japanese, 0.550 for Caucasians, and 0.847 for African-Americans) are comparable with previously reported frequencies of this allele. The allele frequency of the variant 211GϾA observed in this study was comparable to previously reported values for Asian people (0.09 -0.21) (Huang et al., 2000; Sugatani et al., 2002; Ki et al., 2003; Sai et al., 2004) . The variant is considered to be characteristic for Asians. We found only two individuals with this allele out of 150 Caucasians, and no AfricanAmericans had this allele. Innocenti et al. (2002) reported on the haplotype frequencies of UGT1A1 in African-Americans and Caucasians using Ϫ3279TϾG, the TA repeat, and other SNPs in the transcription-regulating region. Although they did not use the marker SNPs 211GϾA and 686CϾA (likely due to their rarity in both populations), frequencies of the *28, *36, *37, and *60 haplotype groups in African-Americans can be calculated according to their data as 0.35, 0.04, 0.12, and 0.33, and the calculated frequencies in Caucasian as 0.36, 0.01, 0.01, and 0.09. These frequencies were also comparable to our data. We found two individuals carrying 211GϾA in the Caucasian group; however, we could not infer haplotypes for these individuals with high certainty. The observed haplotype *28 group frequency in our study of 0.100 (*28b plus *28c) was slightly lower than the reported values of 0.131 in Japanese patients (Sai et al., 2004) and 0.127 in Koreans (Ki et al., 2003) . However, the previously reported values are included in the 95% confidence interval of our data. The observed haplotype *6 group FIG. 2. Expression of wild-type and variant P229L UGT1A1 in COS-1 cells. A, an aliquot (20 g) of the pooled membrane fractions from three independent preparations was subjected to SDS-polyacrylamide gel electrophoresis, electrophoretically transferred to a polyvinylidene difluoride membrane, and immunochemically detected with a rabbit anti-human UGT1A antiserum. The membrane was subsequently stripped and reprobed with a rabbit anti-calnexin antiserum to confirm that the samples were evenly loaded. B, each Western blot from three independent preparations was quantified densitometrically, and the expression level of UGT1A1 proteins was normalized to that of the wild type. The results are expressed as the mean Ϯ S.E.M. from three independent preparations. The expression level of UGT1A1 proteins of P229L was significantly lower than that of the wild type (p ϭ 0.044). 463 frequency (*6a plus *6b) was also comparable to the previously reported data in Japanese and Koreans. A strong association of TA 7 with Ϫ3279G was suggested for Japanese cancer patients (Sai et al., 2004) . This association was also observed in all populations measured in this study. Other variations, TA 5 and TA 8 in the TATA box, also had linkage with Ϫ3279G.
Recent studies indicate that 3Ј-untranslated regions may regulate mRNA stability (Day and Tuite, 1998; Conne et al., 2000) . Exon 1 is unique for each member of the UGT1A subfamily, whereas exons 2 to 5 are common to all members of the subfamily. The variants in the 3Ј-untranslated region of UGT1A1 in exon 5, therefore, could have various effects on all enzymes of the UGT1A subfamily. However, until recently, their physiological effects have remained unknown. Acuna et al. (2003) reported a protective effect of the variant 1941CϾG on liver transaminase levels caused by tolcapone, for which glucuronidation (mainly by UGT1A9) is one metabolic pathway (Acuna et al., 2003) . The SNP 1941CϾG is a marker for haplotype *IB in block 2 as shown in Table 3 . Sai et al. (2004) reported the *IB-dependent decreasing trend of the AUC ratio (SN-38G/SN-38) and an increase in serum total bilirubin levels. Highly differential haplotype distributions in both blocks 1 and 2 observed in different ethnic groups may cause different toxicity profiles during therapy using drugs, such as CPT-11, that are metabolized by UGT1A1.
A novel SNP 686CϾT was found in an African-American sample in this study, leading to an amino acid change, P229L, which is different from the known SNP 686CϾA (P229Q). Studies using a larger sample size may be necessary to elucidate an accurate frequency. The known SNP 686CϾA (P229Q) was reported to be related to Gilbert's syndrome and to have very low bilirubin glucuronidation activity (Koiwai et al., 1995) . However, Jinno et al. (2003a,b) reported that protein expression and mRNA levels of P229Q expressed in COS-1 cells were comparable to those of the wild type, and the decrease in its SN-38 glucuronidation was marginal. Since the association of P229Q with TA 7 has been suggested previously (Huang et al., 2000; Sai et al., 2004) and confirmed in this study, hyperbilirubinemia observed in Japanese and Taiwanese patients carrying the P229Q variant can be mainly attributed to the TA 7 variation. On the other hand, the novel variant P229L expressed in COS-1 cells was found to have extremely low SN-38 glucuronidation efficacy in this study (less than 3% of that for the wild type). The low glucuronidation activity of P229L was not caused by its low transcription levels, because a significant difference in the mRNA level was not observed between the wild type and variant. The low UGT1A1/P229L expression level in COS-1 cells suggests that this enzyme is unstable compared with the wild-type enzyme. Moreover, a band shifted to a higher molecular weight than the wild-type UGT1A1 was detected by a rabbit anti-human UGT1A antibody in a Western blot. Such additional bands were also observed in Western blots of variant UGT1A1 having extremely low enzyme activities, such as F83L and Y486D in our group (Jinno et al., in press ). The band shift to a higher molecular weight in SDS-polyacrylamide gel electrophoresis is considered to be the result of products with different post-translational modifications such as phosphorylation or glycosylation, which may occur due to conformational changes caused by amino acid substitution. This may also contribute to the extremely low catalytic activity of the variant enzyme compared with that of the wild type as shown in Table 4 . Although the clinical significance of 229L remains to be confirmed, this novel SNP may be a potential cause of diseases such as hyperbilirubinemia or jaundice and may cause severe adverse effects after administration of CPT-11. 
